Search

Your search keyword '"Sidhom, Mark"' showing total 247 results
Start Over Author "Sidhom, Mark"
247 results on '"Sidhom, Mark"'

6. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)

Author

Weickhardt, Andrew, Foroudi, Farshad, Lawrentschuk, Nathan, Xie, Jing, Sidhom, Mark, Pal, Abhijit, Grimison, Peter, Zhang, Alison, Ng, Siobhan, Tang, Colin, Hovey, Elizabeth, Chen, Colin, Hruby, George, Guminski, Alexander, McJannett, Margaret, Conduit, Ciara, Tran, Ben, Davis, Ian D., and Hayne, Dickon

Published
2024
Full Text
View/download PDF

8. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

Author

Chesson, Brent, Ali, Muhammad, Chander, Sarat, Moore, Alisha, Cook, Olivia, Eade, Thomas, Sharma, Harish, Ramanathan, Muralidas, Howe, Kate, Frewen, Helen, Siva, Shankar, Bressel, Mathias, Sidhom, Mark, Sridharan, Swetha, Vanneste, Ben G L, Davey, Ryan, Montgomery, Rebecca, Ruben, Jeremy, Foroudi, Farshad, Higgs, Braden, Lin, Charles, Raman, Avi, Hardcastle, Nicholas, Hofman, Michael S, De Abreu Lourenco, Richard, Shaw, Mark, Mancuso, Pascal, Moon, Daniel, Wong, Lih-Ming, Lawrentschuk, Nathan, Wood, Simon, Brook, Nicholas R, Kron, Tomas, Martin, Jarad, and Pryor, David

Published
2024
Full Text
View/download PDF

9. Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver Variability

Author

Sritharan, Kobika, Akhiat, Hafid, Cahill, Declan, Choi, Seungtaek, Choudhury, Ananya, Chung, Peter, Diaz, Juan, Dysager, Lars, Hall, William, Huddart, Robert, Kerkmeijer, Linda G.W., Lawton, Colleen, Mohajer, Jonathan, Murray, Julia, Nyborg, Christina J., Pos, Floris J., Rigo, Michele, Schytte, Tine, Sidhom, Mark, Sohaib, Aslam, Tan, Alex, van der Voort van Zyp, Jochem, Vesprini, Danny, Zelefsky, Michael J., and Tree, Alison C.

Published
2024
Full Text
View/download PDF

14. Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii

Author

Gaudreault, Mathieu, primary, Hardcastle, Nicholas, additional, Jackson, Price, additional, McIntosh, Lachlan, additional, Higgs, Braden, additional, Pryor, David, additional, Sidhom, Mark, additional, Dykyj, Rachael, additional, Moore, Alisha, additional, Kron, Tomas, additional, and Siva, Shankar, additional

Published
2024
Full Text
View/download PDF

15. Evaluating the relationship between contouring variability and modelled treatment outcome for prostate bed radiotherapy

Author

Le Bao, Viet, primary, Haworth, Annette, additional, Dowling, Jason A, additional, Walker, Amy, additional, Arumugam, Sankar, additional, Jameson, Michael, additional, Chlap, Phillip, additional, Wiltshire, Kirsty, additional, Keats, Sarah, additional, Cloak, Kirrily, additional, Sidhom, Mark, additional, Kneebone, Andrew, additional, and Holloway, Lois, additional

Published
2024
Full Text
View/download PDF

17. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Author

Kneebone, Andrew, Fraser-Browne, Carol, Duchesne, Gillian M, Fisher, Richard, Frydenberg, Mark, Herschtal, Alan, Williams, Scott G, Brown, Chris, Delprado, Warick, Haworth, Annette, Joseph, David J, Martin, Jarad M, Matthews, John H L, Millar, Jeremy L, Sidhom, Mark, Spry, Nigel, Tang, Colin I, Turner, Sandra, Wiltshire, Kirsty L, Woo, Henry H, Davis, Ian D, Lim, Tee S, and Pearse, Maria

Published
2020
Full Text
View/download PDF

18. Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial

Author

Keall, Paul, Nguyen, Doan Trang, O'Brien, Ricky, Hewson, Emily, Ball, Helen, Poulsen, Per, Booth, Jeremy, Greer, Peter, Hunter, Perry, Wilton, Lee, Bromley, Regina, Kipritidis, John, Eade, Thomas, Kneebone, Andrew, Hruby, George, Moodie, Trevor, Hayden, Amy, Turner, Sandra, Arumugam, Sankar, Sidhom, Mark, Hardcastle, Nicholas, Siva, Shankar, Tai, Keen-Hun, Gebski, Val, and Martin, Jarad

Published
2020
Full Text
View/download PDF

22. Opioid analgesics for nociceptive cancer pain: A comprehensive review.

Author

Abdel Shaheed, Christina, Hayes, Christopher, Maher, Christopher G., Ballantyne, Jane C., Underwood, Martin, McLachlan, Andrew J., Martin, Jennifer H., Narayan, Sujita W., and Sidhom, Mark A.

Subjects
DRUG toxicity, CODEINE, NONSTEROIDAL anti-inflammatory agents, INTRANASAL administration, MORPHINE, NOCICEPTIVE pain, IMIPRAMINE, IMMUNE system, CANCER pain, ANTIDEPRESSANTS, OPIOID analgesics, ALTERNATIVE medicine, DRUG efficacy, PAIN management, QUALITY of life, NONOPIOID analgesics, TREATMENT effect heterogeneity, FENTANYL, CONSTIPATION, NAUSEA, EVALUATION
Abstract

Pain is one of the most burdensome symptoms in people with cancer, and opioid analgesics are considered the mainstay of cancer pain management. For this review, the authors evaluated the efficacy and toxicities of opioid analgesics compared with placebo, other opioids, nonopioid analgesics, and nonpharmacologic treatments for background cancer pain (continuous and relatively constant pain present at rest), and breakthrough cancer pain (transient exacerbation of pain despite stable and adequately controlled background pain). They found a paucity of placebo‐controlled trials for background cancer pain, although tapentadol or codeine may be more efficacious than placebo (moderate‐certainty to low‐certainty evidence). Nonsteroidal anti‐inflammatory drugs including aspirin, piroxicam, diclofenac, ketorolac, and the antidepressant medicine imipramine, may be at least as efficacious as opioids for moderate‐to‐severe background cancer pain. For breakthrough cancer pain, oral transmucosal, buccal, sublingual, or intranasal fentanyl preparations were identified as more efficacious than placebo but were more commonly associated with toxicities, including constipation and nausea. Despite being recommended worldwide for the treatment of cancer pain, morphine was generally not superior to other opioids, nor did it have a more favorable toxicity profile. The interpretation of study results, however, was complicated by the heterogeneity in the study populations evaluated. Given the limited quality and quantity of research, there is a need to reappraise the clinical utility of opioids in people with cancer pain, particularly those who are not at the end of life, and to further explore the effects of opioids on immune system function and quality of life in these individuals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New Zealand.

Author

Lawless, Anna, Kneebone, Andrew, Armstrong, Shreya, Chander, Sarat, Christie, David, Finnigan, Renee, Hayden, Amy, Higgs, Braden, Knox, Matthew, Sasso, Giuseppe, Sidhom, Mark, Shakespeare, Thomas P, and Holt, Tanya

Subjects
RADICAL prostatectomy, UROLOGISTS, RADIOTHERAPY, ANDROGEN deprivation therapy, ONCOLOGISTS, OLDER men
Abstract

Introduction: This study aimed to investigate the patterns of practices of radiation oncologists (ROs) and urologists in Australia and New Zealand with respect to the utilisation of post‐prostatectomy radiation therapy (RT) and help guide the development of an update to the existing Faculty of Radiation Oncology Genito‐Urinary Group post‐prostatectomy guidelines. Methods: ROs and urologists with subspecialty practice in prostate cancer from Australia and New Zealand were invited to participate in an online survey comprised of clinical scenarios regarding post‐prostatectomy RT. Results: Sixty‐five ROs and 28 urologists responded to the survey. In the setting of low‐risk biochemical relapse, the threshold for initiating RT was lower for ROs than urologists. ROs were more likely than urologists to recommend adjuvant RT for node‐positive disease. When salvage RT was advised for a pT3N0R1 recurrence, there was no consensus amongst ROs on whether to add either ADT or nodal treatment over prostate bed RT alone. For a solitary PSMA‐avid pelvic lymph node recurrence, whole pelvis RT with androgen deprivation therapy was the preferred treatment option (72% ROs, 43% urologists). Most ROs (92%) recommended conventionally fractionated RT to 66–70 Gy, with a boost to any PSMA PET avid recurrent disease. Conclusion: This survey highlights the marked discordance in practice for the management of prostate cancer relapse post‐prostatectomy. This is seen not only between specialties but also within the radiation oncology community. This emphasises the need for an updated evidence‐based guideline to be produced. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Reducing the margin in prostate radiotherapy: optimizing radiotherapy with a general-purpose linear accelerator using an in-house position monitoring system.

Author

Arumugam, Sankar, Wong, Karen, Do, Viet, and Sidhom, Mark

Subjects
LINEAR accelerators, PROSTATE, RADIOTHERAPY, RECTUM
Abstract

Purpose: To study the feasibility of optimizing the Clinical Target Volume to Planning Target Volume (CTV-PTV) margin in prostate radiotherapy(RT) with a general-purpose linear accelerator using an in-house developed position monitoring system, SeedTracker. Methods: A cohort of 30 patients having definitive prostate radiotherapy treated within an ethics-approved prospective trial was considered for this study. The intrafraction prostate motion and the position deviations were measured using SeedTracker system during each treatment fraction. Using this data the CTV-PTV margin required to cover 90% of the patients with a minimum of 95% of the prescription dose to CTV was calculated using van Herk's formula. The margin calculations were performed for treatment scenarios both with and without applying the position corrections for observed position deviations. The feasibility of margin reduction with real-time monitoring was studied by assessing the delivered dose that incorporates the actual target position during treatment delivery and comparing it with the planned dose. This assessment was performed for plans generated with reduced CTV-PTV margin in the range of 7mm-3mm. Results: With real-time monitoring and position corrections applied the margin of 2.0mm, 2.1mm and 2.1mm in LR, AP and SI directions were required to meet the criteria of 90% population to receive 95% of the dose prescription to CTV. Without position corrections applied for observed position deviations a margin of 3.1mm, 4.0mm and 3.0mm was required in LR, AP and SI directions to meet the same criteria. A mean ± SD reduction of 0.5 ± 1.8% and 3 ± 7% of V60 for the rectum and bladder can be achieved for every 1mm reduction of PTV margin. With position corrections applied, the CTV D99 can be delivered within -0.2 ± 0.3 Gy of the planned dose for plans with a 3mm margin. Without applying corrections for position deviations the CTV D99 was reduced by a maximum of 1.1 ± 1.1 Gy for the 3mm margin plan and there was a statistically significant difference between planned and delivered dose for 3mm and 4mm margin plans. Conclusion: This study demonstrates the feasibility of reducing the margin in prostate radiotherapy with SeedTracker system without compromising the dose delivery accuracy to CTV while reducing dose to critical structures. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Implementing online position monitoring for prostate radiotherapy using an in‐house position monitoring system: User experience and impact on workforce.

Author

Cardoso, Michael, Sidhom, Mark, Udovitch, Mark, Young, Tony, and Arumugam, Sankar

Subjects
*USER experience, *RADIOTHERAPY safety, *X-ray imaging, *RADIOTHERAPY, *PROSTATE, *IMAGING systems, *LABOR supply
Abstract

Introduction: To evaluate the feasibility of prostate intrafraction motion monitoring using the SeedTracker real‐time image guidance system in order to improve targeting accuracy in prostate radiotherapy. Methods: SeedTracker was used to monitor prostate gold fiducial seeds with kV x‐ray imaging during radiotherapy in 30 patients. Feedback from radiation therapists was collected via the use of a user evaluation form. The impact on treatment time was established by using a record and verify system. The effective dose and a risk of exposure‐induced cancer death (REID) were estimated for a 60‐year‐old patient when using the SeedTracker system. Results: A total of 22 radiation therapists completed user evaluation forms. The time taken to prepare a reference data set for one patient varied with three (13.6%) radiation therapists taking less than 2 min, 10 (45.5%) between 2 and 4 min, eight (36.4%) between 4 and 6 min and one (4.5%) between 6 and 8 min. The useability of the SeedTracker system was reported as 'easy' by 21 (95.5%) radiation therapists and 'hard' by 1 (4.5%) radiation therapist. Mean treatment time changed from 6 to 7 min with prostate‐only radiotherapy treatment and from 6.9 to 10.2 min with prostate and whole pelvis radiotherapy treatments. The maximum effective dose with the SeedTracker was 1.6276 mSv, and increase in REID was 0.007%. Conclusion: The SeedTracker real‐time image guidance system is a feasible tool to use in radiotherapy departments to monitor and correct for prostate intrafraction motion. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial

Author

Min, Hang, primary, Dowling, Jason, additional, Jameson, Michael G, additional, Cloak, Kirrily, additional, Faustino, Joselle, additional, Sidhom, Mark, additional, Martin, Jarad, additional, Ebert, Martin A, additional, Haworth, Annette, additional, Chlap, Phillip, additional, de Leon, Jeremiah, additional, Berry, Megan, additional, Pryor, David, additional, Greer, Peter, additional, Vinod, Shalini K, additional, and Holloway, Lois, additional

Published
2021
Full Text
View/download PDF

50. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial

Author

Pearse, Maria, Fraser-Browne, Carol, Davis, Ian D., Duchesne, Gillian M., Fisher, Richard, Frydenberg, Mark, Haworth, Annette, Jose, Chakiath, Joseph, David J., Lim, Tee S., Matthews, John, Millar, Jeremy, Sidhom, Mark, Spry, Nigel A., Tang, Colin I., Turner, Sandra, Williams, Scott G., Wiltshire, Kirsty, Woo, Henry H., and Kneebone, Andrew

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results